{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:10:37Z","timestamp":1767838237311,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent advances in the management of Duchenne muscular dystrophy (DMD), such as exon skipping and gene therapy, though have reached a clinical stage, the outcome at its best is still considered suboptimal. In this study, we evaluated a novel N-163 strain of <jats:italic>Aureobasidium pullulans<\/jats:italic> produced \u03b2-glucan\u00a0(Neu-REFIX) for its potential as an adjuvant to slow down the progression of the disease by anti-inflammatory and anti-fibrotic effects. In this study, 45 mice in the three groups, 15 each in a group; Gr. 1 normal mice, Gr.2 mdx mice as vehicle, and Gr.3 mdx mice administered the N-163 \u03b2-glucan for 45\u00a0days. The N-163 \u03b2-glucan group showed a significant decrease in the plasma ALT, AST, and LDH levels (126\u2009\u00b1\u200969\u00a0U\/l, 634\u2009\u00b1\u2009371\u00a0U\/l, 3335\u2009\u00b1\u20091258\u00a0U\/l) compared with the vehicle group (177\u2009\u00b1\u200927\u00a0U\/l, 912\u2009\u00b1\u2009126\u00a0U\/l, 4186\u2009\u00b1\u2009398\u00a0U\/l). Plasma TGF-\u03b2 levels increased, and plasma IL-13 levels decreased in the N-163 group. The inflammation score of HE-stained muscle sections in the N-163 group (1.5\u2009\u00b1\u20090.8) was lower than that in the vehicle group (2.0\u2009\u00b1\u20090.8). The N-163 strain \u03b2-glucan group (24.22\u2009\u00b1\u20094.80) showed a significant decrease in the fibrosis area (Masson\u2019s Trichrome-positive area) compared with the vehicle group\u00a0(36.78\u2009\u00b1\u20095.74). The percentage of centrally nucleated fibres evaluated by Masson\u2019s trichrome staining was 0 in the normal group, while it increased to 80% in the vehicle group but remained at\u00a076.8% in the N-163 group. The N-163 \u03b2-glucan group showed a significant decrease in the fibrosis area. Considering their safety and easy oral consumption, Neu-REFIX\u00a0\u03b2-glucan could be worth large multicentre clinical studies as adjuvant in slowing down the progress of DMD.<\/jats:p>","DOI":"10.1038\/s41598-023-44330-0","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:02:31Z","timestamp":1696863751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced \u03b2-glucan"],"prefix":"10.1038","volume":"13","author":[{"given":"Senthilkumar","family":"Preethy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsura","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajappa","family":"Senthilkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel J. K.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"9","key":"44330_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689533","volume":"19","author":"S Yao","year":"2021","unstructured":"Yao, S. et al. Current pharmacological strategies for Duchenne muscular dystrophy. Front. Cell Dev. Biol. 19(9), 689533 (2021).","journal-title":"Front. Cell Dev. Biol."},{"issue":"10","key":"44330_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/biomedicines9101366","volume":"9","author":"A Tulangekar","year":"2021","unstructured":"Tulangekar, A. & Sztal, T. E. Inflammation in Duchenne muscular dystrophy-exploring the role of neutrophils in muscle damage and regeneration. Biomedicines 9(10), 1366 (2021).","journal-title":"Biomedicines"},{"issue":"1","key":"44330_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli, S. et al. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. Orphanet. J. Rare Dis. 15(1), 141 (2020).","journal-title":"Orphanet. J. Rare Dis."},{"issue":"3","key":"44330_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2613.2002.00221.x","volume":"83","author":"J Lagrota-Candido","year":"2002","unstructured":"Lagrota-Candido, J. et al. Resolution of skeletal muscle inflammation in mdx dystrophic mouse is accompanied by increased immunoglobulin and interferon-gamma production. Int. J. Exp. Pathol. 83(3), 121\u2013132 (2002).","journal-title":"Int. J. Exp. Pathol."},{"key":"44330_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clicom.2021.11.001","author":"N Ikewaki","year":"2021","unstructured":"Ikewaki, N. et al. Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats. Clin. Immunol. Commun. https:\/\/doi.org\/10.1016\/j.clicom.2021.11.001 (2021).","journal-title":"Clin. Immunol. Commun."},{"issue":"1","key":"44330_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40200-022-01170-5","volume":"22","author":"N Ikewaki","year":"2022","unstructured":"Ikewaki, N. et al. Beneficial effects of 1,3\u20131,6 \u03b2-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation. J. Diabetes Metab. Disord. 22(1), 487\u2013494 (2022).","journal-title":"J. Diabetes Metab. Disord."},{"key":"44330_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.06.008","author":"N Ikewaki","year":"2022","unstructured":"Ikewaki, N. et al. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3\u20131,6 biological response modifier glucans in a STAM- animal model of non-alcoholic steatohepatitis. J. Clin. Exp. Hepatol. https:\/\/doi.org\/10.1016\/j.jceh.2022.06.008 (2022).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"44330_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ibneur.2023.06.007","volume":"15","author":"K Raghavan","year":"2023","unstructured":"Raghavan, K. et al. Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3\u20131,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study. IBRO Neurosci. Rep. 15, 90\u201399. https:\/\/doi.org\/10.1016\/j.ibneur.2023.06.007 (2023).","journal-title":"IBRO Neurosci. Rep."},{"issue":"5","key":"44330_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019189","volume":"6","author":"JM Tinsley","year":"2011","unstructured":"Tinsley, J. M. et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 6(5), e19189 (2011).","journal-title":"PLoS One"},{"issue":"2","key":"44330_CR10","first-page":"109","volume":"31","author":"V Nigro","year":"2012","unstructured":"Nigro, V. Improving the course of muscular dystrophy?. Acta Myol. 31(2), 109 (2012).","journal-title":"Acta Myol."},{"issue":"7","key":"44330_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt, E. et al. Life expectancy at birth in Duchenne muscular dystrophy: A systematic review and meta-analysis. Eur. J. Epidemiol. 35(7), 643\u2013653 (2020).","journal-title":"Eur. J. Epidemiol."},{"issue":"1","key":"44330_CR12","first-page":"9","volume":"31","author":"C Angelini","year":"2012","unstructured":"Angelini, C. & Peterle, E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 31(1), 9\u201315 (2012).","journal-title":"Acta Myol."},{"issue":"12","key":"44330_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.omtn.2018.06.005","volume":"7","author":"G Han","year":"2018","unstructured":"Han, G., Lin, C., Ning, H., Gao, X. & Yin, H. Long-term morpholino oligomers in hexose elicits long-lasting therapeutic improvements in mdx mice. Mol. Ther. Nucleic Acids 7(12), 478\u2013489. https:\/\/doi.org\/10.1016\/j.omtn.2018.06.005 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"44330_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijmm.2017.2952","volume":"39","author":"S Murphy","year":"2017","unstructured":"Murphy, S. et al. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. Int. J. Mol. Med. 39(6), 1357\u20131370 (2017).","journal-title":"Int. J. Mol. Med."},{"issue":"7","key":"44330_CR15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.ajpath.2017.02.018","volume":"187","author":"M Abou-Samra","year":"2017","unstructured":"Abou-Samra, M., Boursereau, R., Lecompte, S., Noel, L. & Brichard, S. M. Potential therapeutic action of adiponectin in Duchenne muscular dystrophy. Am. J. Pathol. 187(7), 1577\u20131585 (2017).","journal-title":"Am. J. Pathol."},{"issue":"7","key":"44330_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.nmd.2017.05.009","volume":"27","author":"AS Robertson","year":"2017","unstructured":"Robertson, A. S. et al. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents. Neuromuscul. Disord. 27(7), 635\u2013645 (2017).","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"44330_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/01.ATV.0000019729.39500.2F","volume":"22","author":"E Lutgens","year":"2002","unstructured":"Lutgens, E. et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22(6), 975\u2013982 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"44330_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2017.12.006","volume":"102","author":"SC de Carvalho","year":"2018","unstructured":"de Carvalho, S. C., Matsumura, C. Y., Santo Neto, H. & Marques, M. J. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy. Cytokine 102, 55\u201361 (2018).","journal-title":"Cytokine"},{"issue":"6","key":"44330_CR19","doi-asserted-by":"publisher","first-page":"38371","DOI":"10.1038\/srep38371","volume":"7","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues, M. et al. Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA\/2 background. Sci. Rep. 7(6), 38371 (2016).","journal-title":"Sci. Rep."},{"key":"44330_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2022-000985","volume":"9","author":"S Preethy","year":"2022","unstructured":"Preethy, S. et al. Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and disease. BMJ Open Gastroenterol. 9, e000985. https:\/\/doi.org\/10.1136\/bmjgast-2022-000985 (2022).","journal-title":"BMJ Open Gastroenterol."},{"key":"44330_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14283\/jarlife.2023.11","volume":"12","author":"N Ikewaki","year":"2023","unstructured":"Ikewaki, N. et al. Beta 1,3\u20131,6 glucans produced by two novel strains of Aureobasidium pullulans exert immune and metabolic beneficial effects in healthy middle-aged Japanese men: Results of an exploratory randomized control study. J. Aging Res. Lifestyle 12, 61\u201371. https:\/\/doi.org\/10.14283\/jarlife.2023.11 (2023).","journal-title":"J. Aging Res. Lifestyle"},{"key":"44330_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112243","author":"K Raghavan","year":"2021","unstructured":"Raghavan, K. et al. Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3\u20131,6 glucans on interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomed. Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2021.112243 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"44330_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.12688\/f1000research.15889.2","volume":"7","author":"N Gajendran","year":"2018","unstructured":"Gajendran, N. The root cause of Duchenne muscular dystrophy is the lack of dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se. F1000Research 7, 1321. https:\/\/doi.org\/10.12688\/f1000research.15889.2 (2018).","journal-title":"F1000Research"},{"issue":"1","key":"44330_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13148-021-01001-z","volume":"13","author":"A Rugowska","year":"2021","unstructured":"Rugowska, A., Starosta, A. & Konieczny, P. Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy. Clin. Epigenet. 13(1), 13 (2021).","journal-title":"Clin. Epigenet."},{"issue":"3","key":"44330_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/jor.22236","volume":"31","author":"C Isaac","year":"2013","unstructured":"Isaac, C. et al. Dystrophin and utrophin \u201cdouble knockout\u201d dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities. J. Orthop. Res. 31(3), 343\u2013349. https:\/\/doi.org\/10.1002\/jor.22236 (2013).","journal-title":"J. Orthop. Res."},{"issue":"14","key":"44330_CR26","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/hmg\/ddl151","volume":"15","author":"K Ito","year":"2006","unstructured":"Ito, K. et al. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum. Mol. Genet. 15(14), 2266\u20132275 (2006).","journal-title":"Hum. Mol. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44330-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T03:30:25Z","timestamp":1700364625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44330-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44330"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44330-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans. The remaining authors do not have any competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17008"}}